New trial aims to halt prostate cancer spread with targeted radiation
NCT ID NCT07477626
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing whether adding pelvic radiotherapy to standard hormone therapy can delay cancer progression in men whose prostate cancer has spread to nearby lymph nodes after prostate removal surgery. About 372 participants will be randomly assigned to receive either hormone therapy alone or hormone therapy plus radiation. The study will track cancer recurrence, survival, and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Androgen deprivation therapy (hormone therapy) and pelvic radiotherapy
- What this could lead to
- If successful, this could establish a new standard of care that delays cancer progression and improves survival for men with node-positive prostate cancer after surgery.
- What could go wrong
- This is a Phase 3 trial, but results are not yet available. Adding radiotherapy may increase side effects without clear benefit, and the study only includes specific patient types, so findings may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGEN DEPRIVATION THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Guangdong Medical University
NOT_YET_RECRUITINGZhanjiang, Guangdong, China
-
Beijing Hospital
RECRUITINGBeijing, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, China
-
Dongguan People's Hospital
NOT_YET_RECRUITINGDongguan, Guangdong, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Peking University First Hospital
RECRUITINGBeijing, China
-
Peking University Third Hospital
NOT_YET_RECRUITINGBeijing, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Naval Medical University
NOT_YET_RECRUITINGShanghai, China
-
The First Affiliated Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer spot prostate cancer return better than the standard scan?
- New drug could offer safer option after prostate cancer surgery
- Which gas pump causes less pain during robotic prostate surgery? a Head-to-Head trial
- Exercise may counteract side effects of prostate cancer hormone therapy
- New radiation approach aims to tame High-Risk prostate cancer
- New drug combo aims to stop aggressive breast cancer from returning